eik1005
eik1005: developed by 1 company · 1 clinical trial tracked.
eik1005 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could eik1005 → EIKN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Eikon Therapeutics Inc. (EIKN) | Phase 1/Phase 2 |
Clinical Trials (1)
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
Primary endpoint: Dose-Limiting Toxicity (DLT) - Part 1
Frequently asked questions
Who is developing eik1005?
eik1005 is being developed by Eikon Therapeutics Inc..
How many clinical trials involve eik1005?
BioSniper tracks 1 clinical trial involving eik1005.